[1] 闫贤良,程宇彤,王苏,等. 经股动脉PCI术中比伐芦定与普通肝素的临床比较[J].中国循证心血管医学杂志,2017,9(9):1045-1047.
[2] Shahzad A,Kemp I,Mars C,et al. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEATPPCI): an open-label, single centre, randomised controlled trial[J].Lancet,2014,384(9957):1849-1858.
[3] Han Y,Guo J,Zheng Y,et al. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial[J].JAMA,2015,313(13):1336-1346.
[4] 中国医师协会急诊医师分会,中华医学会心血管病学分会,中华医学会检验医学分会. 急性冠脉综合征急诊快速诊疗指南[J].中华急诊医学杂志,2016,25(4):397-404.
[5] Corsten MF,Dennert R,Jochems S,et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease [J].Circ Cardiovasc Genet,2010,3(6):499-506.
[6] 徐峥嵘,陈军,陈力,等. 比伐芦定在高出血风险患者介入治疗中抗凝疗效和安全性评价[J].中国心血管病研究,2017,15(7):659-663.
[7] Lincoff AM,Bittl JA,Harrington RA,et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial [J].JAMA,2003,289(7):853-863.
[8] 何伟民,黄景文,罗韶金,等. 替格瑞洛联合比伐芦定对急性ST段抬高型心肌梗死患者急诊PCI术中无复流/慢血流的作用[J].血栓与止血学,2017,23(3):400-402.
[9] Valgimigli M,Frigoli E,Leonardi S,et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes[J].N Engl J Med,2015,373 (11):997-1009.
[10] Stone GW,Witzenbichler B,Guagliumi G,et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial[J].Lancet,2011,377(9784):2193-2204. |
2018, Vol. 35 
